ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 119,262 shares of the specialty pharmaceutical company's stock after selling 4,570 shares during the quarter. Bank of New York Mellon Corp owned 0.55% of ANI Pharmaceuticals worth $7,985,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ANIP. GAMMA Investing LLC raised its position in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after acquiring an additional 881 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $166,000. Rafferty Asset Management LLC purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at approximately $200,000. Bridgefront Capital LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter worth $204,000. Finally, Freestone Grove Partners LP acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter worth $259,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $64.88, for a total value of $25,952.00. Following the completion of the sale, the vice president owned 78,945 shares in the company, valued at approximately $5,121,951.60. This trade represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president directly owned 89,897 shares in the company, valued at $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,681 shares of company stock worth $345,222. 11.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Trading Up 1.1%

ANI Pharmaceuticals stock traded up $0.71 during midday trading on Friday, reaching $67.48. The stock had a trading volume of 416,041 shares, compared to its average volume of 284,009. The stock's 50-day simple moving average is $63.46 and its 200 day simple moving average is $63.05. The stock has a market capitalization of $1.46 billion, a PE ratio of -53.13 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The company's revenue was up 43.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 EPS. Analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on ANIP shares. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Finally, HC Wainwright initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 10th. They issued a "buy" rating and a $84.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $78.88.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.